Immunotherapy CEO Jeff Galvin Joins the Board of Directors of the Cancer Support Community

<span>ROCKVILLE, MD, UNITED STATES, September 6, 2018 /EINPresswire.com/ -- Jeff Galvin, a former Silicon Valley CEO, and now a leader in the field of gene and cell therapy to cure cancer and other human diseases, has joined the Board of Directors of the Cancer Support Community (CSC). Galvin&rsquo;s biotech company, American Gene Technologies International...</span>

ROCKVILLE, MD, UNITED STATES, September 6, 2018 /EINPresswire.com/ -- Jeff Galvin, a former Silicon Valley CEO, and now a leader in the field of gene and cell therapy to cure cancer and other human diseases, has joined the Board of Directors of the Cancer Support Community (CSC). Galvin’s biotech company, American Gene Technologies International Inc. (AGT), is striving to create the next big revolution in cancer therapies with Gamma Delta T Cell immunotherapy, which uses a method to stimulate the immune system to kill solid cancer tumors.

CSC is the largest professionally led non-profit network of cancer support world-wide with a network of 175 locations, providing $50 million in free support services to patients and families. CSC’s mission is to ensure that “people impacted by cancer are empowered by knowledge, strengthened by action, and sustained by community.”

Jeffrey A. Galvin<br/&gtCEO and Founder
Jeffrey A. Galvin CEO and Founder

AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including: large and orphan indications, infectious disease, immune-oncology, and monogenic disorders. AGT expects to take its patented, lead candidate for an HIV Cure into the clinic in 2019. It has pioneered a novel immuno-oncology approach of stimulating gamma-delta (γδ) T cells to attack a variety of cancers. Four key patents in AGT’s novel immuno-oncology approach have been granted. AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine.

Clicking the image will take you to the original article

Source: www.americangene.com